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Abstract: Skin cancer is the most common form of cancer types. It is generally divided into two 
categories: melanoma (∼ 5%) and nonmelanoma (∼ 95%), which can be further categorized into 
basal cell carcinoma, squamous cell carcinoma, and some rare skin cancer types. Biopsy is still 
the gold standard for skin cancer evaluation in the clinic. Various anatomical imaging techniques 
have been used to evaluate different types of skin cancer lesions, including laser scanning 
confocal microscopy, optical coherence tomography, high-frequency ultrasound, terahertz 
pulsed imaging, magnetic resonance imaging, and some other recently developed techniques 
such as photoacoustic microscopy. However, anatomical imaging alone may not be sufﬁ  cient 
in guiding skin cancer diagnosis and therapy. Over the last decade, various molecular imaging 
techniques (in particular single photon emission computed tomography and positron emission 
tomography) have been investigated for skin cancer imaging. The pathways or molecular targets 
that have been studied include glucose metabolism, integrin αvβ3, melanocortin-1 receptor, 
high molecular weight melanoma-associated antigen, and several other molecular markers. 
Preclinical molecular imaging is thriving all over the world, while clinical molecular imaging 
has not lived up to the expectations because of slow bench-to-bedside translation. It is likely that 
this situation will change in the near future and molecular imaging will truly play an important 
role in personalized medicine of melanoma patients.
Keywords: skin cancer, molecular imaging, melanoma, anatomical imaging, positron emission 
tomography, antibody
Introduction
Skin cancer is the most common form of cancer in the United States with more than 
1 million new cases diagnosed annually (http://www.skincancer.org). It is estimated 
that one in ﬁ  ve Americans and one in three Caucasians will develop skin cancer in 
their lifetime (http://www.cancer.gov). Skin cancers are generally divided into two 
categories: melanoma (the most serious form of skin cancer) and nonmelanoma 
(Mueller and Reichrath 2008; Rass and Tilgen 2008). Nonmelanoma can be further 
categorized into two main types: basal cell carcinoma (BCC) and squamous cell 
carcinoma (SCC) (Figure 1). BCC, the most common form of skin cancer, is rarely 
fatal but can be highly disﬁ  guring. SCC is the second most common form of skin 
cancer. Together, BCC and SCC constitutes approximately 95% of nonmelanoma skin 
cancers (NMSCs) (Tillman and Carroll 2007). Besides the cancer types mentioned 
above, there are also certain unusual skin cancer types such as Merkel cell carcinoma 
and Kaposi’ sarcoma (Douglas et al 2007; Tai 2008). Some precancerous lesion, such 
as actinic keratosis (Rossi et al 2007; Schwartz et al 2008), has also been reported.
If skin cancers are diagnosed and treated early, they are nearly 100 percent curable. 
However, correct diagnosis can not always be unequivocally reached. Direct visual 
inspection of the skin, depending on the experience of the clinician, is often suboptimal 
for skin cancer diagnosis. Currently, conventional histopathology detection (biopsy) is 
still the gold standard for skin cancer evaluation. However, there are many disadvantages 
associated with biopsy. It is painful, relatively expensive, time-consuming, and typically Clinical, Cosmetic and Investigational Dermatology 2008:1 2
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accompanied with scar formation. In many cases, several 
biopsies will be needed before a diagnosis can be conﬁ  rmed. 
Furthermore, histology does not allow repeated observation 
of dynamic processes over time, such as monitoring the 
therapeutic effects of a certain drug.
To overcome such disadvantages, many imaging 
modalities have been investigated for noninvasive diagnosis 
of skin cancer. Various anatomical imaging techniques, and 
more recently molecular imaging techniques, have been 
used to evaluate different types of skin cancer lesions. In this 
review article, we will summarize the progress to date on 
anatomical and molecular imaging techniques of skin cancer. 
With the ultimate goal beyond more accurate, pain-free diag-
nosis, some of these methods can also be used for monitoring 
the therapeutic efﬁ  cacy of skin cancer intervention.
Anatomical imaging
Development of noninvasive, high-resolution techniques for 
anatomically imaging skin cancers or skin related lesions in 
situ can increase the diagnostic accuracy. The most promising 
techniques with anatomical accuracy include laser scanning 
confocal microscopy (CM) (Astner et al 2008; Gerger et al 
2008; Nehal et al 2008), optical coherence tomography 
(OCT) (Gambichler et al 2007a; Gambichler et al 2007b; 
Salvini et al 2008), high-frequency ultrasound (HFUS) (Dill-
Muller and Maschke 2007; Schmid-Wendtner and Burgdorf 
2005), terahertz pulsed imaging (TPI) (Mogensen and Jemec 
2007; Wallace et al 2004), and magnetic resonance imaging 
(MRI) (Campbell and Campbell 2006; Mogensen and Jemec 
2007). CM has exceptional spatial resolution yet it suffers 
from poor tissue penetration. OCT, HFUS, and MRI can 
acquire full thickness, vertical optical sections, however their 
resolution is relatively limited and can not reach the cellular 
level. There are also some recently developed techniques 
for skin cancer imaging, such as ﬂ  uorescence remission 
sensoring (Wollina et al 2007), Raman spectroscopy (Lieber 
et al 2008; Naito et al 2008), and photoacoustic microscopy 
(Zhang et al 2006).
Confocal microscopy
CM, ﬁ  rst described about half a century ago (Minsky 1988), is 
a technique in which a laser is focused on the speciﬁ  c point in 
the skin to selectively collect light from in-focus planes in the 
tissue. It offers the highest resolution (comparable to routine 
histology) among all these techniques. The latest CM systems 
can offer micrometer (µm)-level axial resolution and sub-µm 
lateral resolution (Astner et al 2008; Gerger et al 2008; Nehal 
et al 2008). Therefore, it is possible to study the skin on the 
cellular/subcellular level in vivo with CM and application 
of this imaging modality to skin visualization during the last 
decade has been an exciting area in dermatology (Gonzalez 
and Gilaberte-Calzada 2008; Nehal et al 2008).
As a noninvasive imaging method, CM is frequently used 
for the diagnosis of skin cancer (Gerger et al 2008; Mogensen 
and Jemec 2007; Ulrich et al 2007). Basal and squamous 
cell carcinomas (Agero et al 2006; Horn et al 2007; Patel 
et al 2007; Tillman and Carroll 2007), melanocytic nevi and 
melanomas (Gerger et al 2008; Happe et al 1997; Langley 
et al 2007; Ono et al 2006; Pellacani et al 2005b), as well 
as actinic keratoses (Aghassi et al 2000; Ulrich et al 2008), 
have all been imaged successfully with CM. In melanocytic 
lesions, the endogenous contrast provided by melanin and 
melanosomes can allow for the differentiation of benign 
versus malignant tissues. In nonmelanoma lesions, the 
morphologic characteristics visualized by CM has been 
reported to be in good correlation with histology (Astner et al 
2008). For example, common features of actinic keratose and 
BCC in CM images include nuclear pleomorphism in the 
granular and spinous layer, and increased vascularity in the 
superﬁ  cial dermal compartment (Ulrich et al 2008).
Three-dimensional (3D) reconstruction of skin tumors 
using CM was reported in 2006 (Ono et al 2006). Such 
reconstruction, using more sophisticated computing 
algorithm and potentially enabling more accurate imaging, 
was able to successfully differentiate benign and malignant 
skin tissues. More research needs to be undertaken before 
such 3D CM can be used for clinical applications. Taken 
together, CM imaging is a promising noninvasive tool in the 
differential diagnosis of benign and malignant pigmented 
skin lesions. Greater than 90% positive predictive value has 
been reported for the differentiation of benign and malignant 
skin lesions (melanoma and BCC) (Gerger et al 2006).
The advantages of in vivo CM over conventional 
histology are several-fold. First, CM is painless and 
noninvasive which does not cause tissue damage or require 
staining. Second, the data collection process is quite fast 
and can allow for repeated observation of dynamic process 
in real time. Therefore, CM has been used for longitudinal 
evaluation of physiological events (Patel et al 2007; Pellacani 
et al 2005a; Segura et al 2007), disease progression over 
time (Agero et al 2006; Scope et al 2007), and response to 
therapy (Astner et al 2008; Paolino et al 2008). On the other 
hand, there are also many disadvantages associated with 
CM. First, the depth of imaging (about 250 µm) is limited 
to the superﬁ  cial dermis due to tissue-induced scattering and 
aberrations. Second, the grayscale contrast in the CM image Clinical, Cosmetic and Investigational Dermatology 2008:1 3
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lacks speciﬁ  city for organelles and ultrastructure. Lastly, CM 
is encumbered by the small ﬁ  eld of view and the mirror-based 
design. The instrumentation is relatively expensive and large, 
therefore difﬁ  cult to use on certain anatomical sites. Taking 
all the factors into consideration, CM can serve as a powerful 
imaging modality for improving the diagnostic accuracy of 
skin cancer, yet it should not be used independently without 
other techniques.
Optical coherence tomography
OCT, based on light scattering, can be used to image 
microscopic structures in vivo at a resolution of a few µm and 
to a depth of 1–3 mm (Gambichler et al 2007a; Gambichler 
et al 2007b; Salvini et al 2008). It is analogous to B-mode 
ultrasound pulse-echo imaging except that the optical 
rather than the acoustic reﬂ  ectivity is measured. Linear 
characteristics such as scattering, absorption, birefringence, 
and refractive index are measured to produce the OCT 
images, which can also be enhanced by Doppler function. 
Capable of acquiring cross-sectional, high-resolution images 
of structures below the tissue surface (Fujimoto et al 2000; 
Gambichler et al 2005; Pierce et al 2004), OCT can enable the 
differentiation of healthy tissue from cancerous tissue based 
on simple visual analysis, which can be quite difﬁ  cult with 
other techniques since typically there is no boundary between 
the cancerous and normal tissue (Gambichler et al 2007a). 
Recently, OCT was used to evaluate skin vascular lesions, 
which provided a new perspective for OCT in noninvasive 
diagnostics (Salvini et al 2008). OCT is currently being 
evaluated clinically in several countries, and it as already 
been approved for medical diagnosis in several others 
(Fujimoto 2003; Fujimoto et al 2000).
Although OCT has been investigated in many areas of 
dermatology, it was not systematically studied in skin can-
cer (eg BCC and melanoma) until 2006 (Gambichler et al 
2007a; Gambichler et al 2007b; Olmedo et al 2006). In BCC, 
OCT is capable of visualizing altered skin architecture with 
good correlation to histopathology. Compared to the normal 
tissue, a loss of normal skin architecture and disarrangement 
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Figure 1 The characteristic histology of melanoma, BCC, SCC, and some rare skin cancer subtypes (Kaposi’s sarcoma and Merkel cell carcinoma).   Adapted from (Carless 
and Grifﬁ  ths 2008; Crowson 2006).Clinical, Cosmetic and Investigational Dermatology 2008:1 4
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images of BCCs. Features that were frequently identiﬁ  ed 
by OCT include large plug-like signal-intense structures, 
honeycomb-like signal-free structures, and the prominent 
signal-free cavities in the upper dermis (Gambichler 
et al 2007a), all of which correlated well with the 
histologic ﬁ  ndings. Such consistency with histology was 
also established in benign or malignant melanocytic skin 
lesions (Gambichler et al 2007b). Melanoma often showed 
marked architectural disarray, rarely displaying a clear 
dermoepidermal border, when compared with benign nevi. 
The icicle-shaped structures were the most striking OCT 
feature of melanoma, which were not present in benign 
nevi. Since OCT is a relatively new technique for skin 
cancer diagnosis, there is not enough data yet to support 
the clinical use of OCT only for the differentiation of skin 
cancer subtypes. The diagnostic performance of OCT in 
melanoma can not be fully determined without histological 
conﬁ  rmation.
Another application of OCT is to estimate the superﬁ  cial 
thickness of skin cancers (eg, BCCs) to facilitate surgery 
preparation (Olmedo et al 2007). Measurement of the depth 
and thickness of different types of BCC neoplasms with 
OCT exhibited excellent correlation with histopathological 
measurement (Olmedo et al 2007). The accuracy of 
OCT measurement is relatively high, typically more than 
80% (Gladkova et al 2004). One limitation of OCT is that it is 
very difﬁ  cult to differentiate inﬂ  ammatory processes, cancer, 
and scarring with this technique (Roman Kuranov 2002). 
Comparing to ultrasound imaging, OCT is capable of showing 
very small cystic structures more distinctly. However, in terms 
of assessing the margins of the tumor, ultrasound is probably 
a better choice (Buchwald et al 2003).
Ultrasound
Since its initial appearance about 50 years ago, ultrasound 
has become an essential tool for medical diagnosis. It is a 
versatile, painless, low-risk, noninvasive procedure which 
can be done virtually anywhere and can be readily repeated. 
In dermatology, high-frequency sonography (20 MHz) 
and mid-frequency sonography (7.5–15 MHz) have been 
well-established in the diagnostic work-up of benign and 
malignant diseases of the skin (Desai et al 2007; Dill-Muller 
and Maschke 2007). The basic modes of ultrasound include 
the A-mode, B-mode, and Doppler method (Dill-Muller and 
Maschke 2007).
At a frequency of 20 MHz, tissue penetration depth of 
approximately 6 to 7 mm can be achieved. In normal skin, 
the dermis is markedly echogenic and sharply demarcated 
from the hypoechogenic subcutaneous fat (Desai et al 
2007). The ﬁ  brillar network of the dermis is responsible for 
its echogenicity in ultrasound (Dummer et al 1995; Lassau 
et al 1999; Lassau et al 1997). HFUS can readily distinguish 
solid lesions (eg BCCs or malignant melanomas) from cystic 
structures (Chin et al 2003; Schmid-Wendtner and Burgdorf 
2005). Although an assertive diagnosis between malignant 
and benign lesions cannot be made based on HFUS alone, the 
lesion margins can be outlined (Desai et al 2007; Milner et al 
1997; Schafer-Hesterberg et al 2007). Cancerous skin tissue, 
such as BCC, has special friability which can cause decreased 
signal penetration of HFUS. Therefore, BCCs typically 
appear more hypoechogenic than the normal skin tissue. Due 
to its noninvasive, easily repeatable nature, HFUS has been 
used for evaluating the therapeutic efﬁ  cacy of photodynamic 
therapy of BCC (Moore and Allan 2003).
In melanoma patients, the primary lesion is close to the 
skin surface which makes it a desirable target for HFUS 
examination (Choi and Gershenwald 2007; Lassau et al 
2007). HFUS can image primary cutaneous melanomas, uveal 
melanomas, and the regional lymph nodes draining the skin 
that lie in the axilla, groin, neck and other locations. Although 
ultrasound study of primary melanomas in the skin and eye has 
provided some useful insights, the major role of ultrasound in 
melanoma diagnosis is to provide early detection of regional 
lymph node metastases (King 2006; Schafer-Hesterberg et al 
2007; Uren et al 2007). HFUS is clearly superior to palpation 
of the nodes during follow-up and, when combined with 
guided ﬁ  ne-needle biopsy, allows for the earliest possible 
surgical intervention for regional nodal metastases. The use of 
ultrasound contrast agents may further improve the sensitivity 
of ultrasound in the detection of very small metastatic tumor 
foci (Lassau et al 2007; Uren et al 2007).
Consistency between histology and HFUS results, as 
well as the statistical correlation between these techniques, 
has been well documented (Clement et al 1998; Harland 
et al 1993; Jovanovic et al 2005; Lassau et al 1997; Milner 
et al 1997). HFUS is certainly not going to replace histology 
in the evaluation of skin cancer, however it can be a very 
useful adjunct in the surgical planning. HFUS enables 
live, 3-D analysis of the tumor, allowing for the in-depth 
examination of a skin cancer far beyond what the naked eye 
(or CM) can visualize, whereas histological analysis can only 
offer a 2-D view of the biopsied tissue sample.
Terahertz pulsed imaging
Recently, terahertz technology has become a new tool for 
material characterization which may also serve as a potential Clinical, Cosmetic and Investigational Dermatology 2008:1 5
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tool for disease diagnosis (Fitzgerald et al 2002; Lofﬂ  er 
et al 2002; Mogensen and Jemec 2007; Walker et al 2004). 
Radiation in the far infrared region of the electromagnetic 
spectrum, between 60 gigahertz and 4 terahertz, is called 
terahertz radiation. Since the energy in this frequency range 
excites the intermolecular interactions, such as the librational 
and vibrational modes of molecules, the data acquired can 
provide important spectroscopic information. As a coherent 
technique, both the amplitude and phase of the terahertz pulse 
can be obtained, from which the broadband absorption and 
refractive index of a medium can be determined respectively. 
Because the absorption is generally due to the chemical 
constituents of the medium, the speciﬁ  c signatures of a 
disease can be measured to provide diagnostic information. 
In addition, the refractive index of the tissue being imaged 
can also potentially provide images with both morphological 
and functional information.
TPI studies have revealed a significant difference 
between ex vivo BCC and healthy skin tissue with decent 
accuracy (17 out of 21) (Woodward et al 2003). Evidence 
from positron emission tomography (PET) and MRI studies 
has indicated that tumors have increased water content 
(Bruehlmeier et al 2003; Chen et al 1992). With strong 
absorption across the entire terahertz range (Ueno and Ajito 
2008), the changes in water content can provide a source 
of image contrast. In one study, TPI analysis of 18 BCC 
tissues both in vivo and ex vivo revealed contrast in all TPI 
images which correlated well with histology (Wallace et al 
2004). Although the diagnostic accuracy of TPI is quite 
satisfactory, it can not discriminate various skin cancer 
subtypes therefore can not differentiate the benign lesions 
from the malignant ones. Overall, TPI may help surgery 
planning in the future, yet there is still a long way to go 
before its clinical application.
Magnetic resonance imaging
MRI makes use of the magnetic properties of proton or 
other nuclei to generate high-resolution images. The major 
advantage of MRI over most other imaging modalities is the 
exquisite soft tissue contrast with good spatial resolution 
(100 µm). However, the major disadvantage is the low 
sensitivity which typically requires long scanning time even 
with the use of exogenous contrast agents.
Because of its superb soft tissue contrast, MRI can 
readily reveal the anatomical abnormality of skin tumors to 
obtain morphologic information about the shape, depth, and 
location of the tumor (Rajeswari et al 2003). MRI is a good 
but comparatively expensive tool for therapy planning in skin 
cancers such as BCC, SCC, and Kaposi’s sarcoma (Guy et al 
1994; Peters and Vejlsgaard 1992). In melanoma, MRI 
can produce distinctive MR characteristics because of the 
presence of blood products and melanin. Approximately half 
of the melanoma metastases are hyperintense on T1-weighted 
images before the administration of gadolinium, whereas the 
cerebral metastases rarely demonstrate T1 hyperintensity 
(Choi and Gershenwald 2007; Garbe and Eigentler 2007; 
Moulin-Romsee et al 2008).
MRI can also be used for evaluating the therapeutic 
response of melanoma and BCC (Buijs et al 2008; Rupprecht 
et al 2007). The apparent diffusion coefﬁ  cient calculated 
from diffusion-weighted MRI has become a promising 
biomarker for tumor response to therapy (Vossen et al 2006). 
Measuring the mobility of water can reveal the status of the 
tumor tissue in that viable tissue restricts water mobility due 
to the intact cell membrane, while the necrotic tissue has 
higher membrane permeability which results in an increased 
diffusion coefﬁ  cient. With this technology, we can monitor 
the responses of skin cancers to chemotherapy or radiotherapy 
with high efﬁ  ciency and convenience which can facilitate 
further optimization of the therapeutic strategy.
In summary, the cross-sectional MRI of disease extent 
in skin cancer is quite accurate which can give the clinician 
adequate information regarding the type and extent of surgery 
required. Not only can MRI provide diagnostic information, it 
can also indicate the outcome of therapeutic intervention.
Other anatomical imaging techniques
Besides the abovementioned modalities, several other imaging 
methods still at the early stages of development are also 
suitable for skin-related imaging. These techniques include 
fluorescence remission sensoring (Wollina et al 2007), 
Raman spectroscopy (Lieber et al 2008; Naito et al 2008), and 
photoacoustic microscopy (Zhang et al 2006). Fluorescence 
remission sensoring was applied in a preliminary study to 
differentiate the subtypes of NMSC (Wollina et al 2007). 
Some differences were observed between BCC and actinic 
keratoses, which may aid in the accurate diagnosis of skin 
cancer (Wollina et al 2007). Raman spectroscopy has also been 
applied, using near-infrared (NIR, 700–900 nm) excitation, to 
evaluate the skin structure (Lieber et al 2008; Naito et al 2008). 
Functional photoacoustic microscopy was used to image 
angiogenesis of melanoma in vivo (Zhang et al 2006), which 
could give not only anatomical information but also certain 
functional characteristics of the diseased tissue.
Noninvasive anatomical imaging has become an 
indispensable tool for skin cancer diagnosis, in addition Clinical, Cosmetic and Investigational Dermatology 2008:1 6
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to conventional biopsy. Imaging can give (whole body) 
readout in an intact system which is much more relevant 
and reliable than in vitro/ex vivo assays; provide more 
statistically accurate results since longitudinal studies can 
be performed in the same subjects which serves as its own 
control; aid in lesion detection in cancer patients and patient 
stratiﬁ  cation; and help in individualized anti-cancer treatment 
monitoring and dose optimization. Each of these anatomical 
imaging techniques has its advantages and disadvantages 
(Table 1). Although they can be very helpful in many settings, 
anatomical imaging alone is not sufﬁ  cient to guide diagnosis 
and therapy since the biological/molecular changes occur 
long before any anatomical differences can be detected. In the 
following text, we will summarize the current state-of-the-art 
of molecular imaging of skin cancer, which can give pivotal 
information about the biological/molecular changes in an 
intact system.
Molecular imaging of skin cancer
The ﬁ  eld of molecular imaging, recently deﬁ  ned by the 
Society of Nuclear Medicine (SNM) to be “the visualization, 
characterization and measurement of biological processes at 
the molecular and cellular levels in humans and other living 
systems” (Mankoff 2007), has ﬂ  ourished over the last decade. 
In general, molecular imaging modalities include molecular 
MRI (mMRI), magnetic resonance spectroscopy (MRS), 
optical bioluminescence, optical fluorescence, targeted 
ultrasound, single photon emission computed tomography 
(SPECT), and PET (Massoud and Gambhir 2003). Continued 
development and wider availability of scanners dedicated to 
small animal imaging studies, which can provide a similar 
in vivo imaging capability in mice, primates, and humans, 
can enable smooth transfer of knowledge and molecular 
measurements between species thereby facilitating 
clinical translation.
Molecular imaging takes advantage of the traditional 
diagnostic imaging techniques and introduces molecular 
imaging agents (probes) to determine the expression of 
indicative molecular markers at different stages of diseases. 
A molecular imaging agent, deﬁ  ned as “a probe used to 
visualize, characterize, and measure biological processes in 
living systems” (Mankoff 2007), is typically composed of an 
imaging label, a carrier that contains (a) targeting ligand(s) or 
is a targeting ligand, and a linker between the carrier and the 
label. Many factors need to be optimized simultaneously to 
obtain the best imaging outcome. Noninvasive detection of 
the molecular markers can allow for much earlier diagnosis, 
earlier treatment, and better prognosis that will eventually 
lead to personalized medicine.
Most of the molecular imaging studies of skin cancer 
targets melanoma since it is highly metastatic and is the most 
deadly disease among all skin cancer subtypes. The molecular 
pathway/targets that have been investigated include glucose 
metabolism, integrin αvβ3, melanocortin-1 receptor (MC1R), 
high molecular weight melanoma-associated antigen 
(HMWA), and several others.
Imaging glucose metabolism
PET, a radionuclide-based imaging technique, has been 
used for the diagnosis, staging, and restaging after 
treatment or recurrence of various cancer types including 
melanoma (Kumar and Alavi 2005). The increased 
metabolism of glucose in malignant viable cells makes 
18F-fluorodeoxyglucose (18F-FDG, Figure 2) the most 
commonly used PET radiopharmaceuticals (Gambhir et al 
2001). Like glucose, 18F-FDG is transported into the tumor 
Table 1 Comparison of the anatomical imaging modalities that have been used for skin cancer diagnosis
CM OCT HFUS TPI MRI
Resolution 1–5 µm 2–20 µm 50–300 µm 20–200 µm 25–100 µm
Penetration ∼250 µm 1–3 mm 6–7 mm Frequency dependent 
(typically 1 mm)
no limit
Diagnosis accuracy +++ ++ ++ + +++
Contrast agent? not needed not needed sometimes not needed sometimes
Spectra used near-infrared infrared around 20 MHz terahertz wave radiowaves










high accuracy, exquisite 
tissue contrast
Major disadvantages limited penetration, 
small ﬁ  eld-of-view, 
extensive training
hard to distinguish 
tumor from scar 






expensive, low sensitivity, 
slow acquisitionClinical, Cosmetic and Investigational Dermatology 2008:1 7
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cells by glucose transporters. After phosphorylation by 
hexokinase, the 18F-FDG-6-phosphate is trapped inside the 
cell (which gives tumor contrast) because it is not a substrate 
for glucose-6-phosphate isomerase. Since there is usually 
many-fold increase in glucose metabolism in malignant 
tumors as compared with the normal tissue, 18F-FDG PET 
has been extensively explored for cancer imaging (Gambhir 
et al 2001).
In 1991, the ﬁ  nding that 18F-FDG can be preferentially 
taken up in murine melanoma xenografts eventually led to 
the use of 18F-FDG PET in melanoma patient management 
(Wahl et al 1990a). 18F-FDG PET has since been studied in 
many different scenarios in melanoma patients. For initial 
staging of melanoma, 18F-FDG PET has lower sensitivity 
than sentinel lymph node (SLN) biopsy, therefore it cannot 
replace SLN biopsy for regional lymph node staging (Acland 
et al 2001; Hafner et al 2004; Macfarlane et al 1998). Since 
melanoma can metastasize widely into various organs and 
tissues (Rusciano 2000; Streit and Detmar 2003), currently 
18F-FDG PET is most commonly used for suspected or known 
distant metastases in patients with melanoma (Figure 2) 
(Belhocine et al 2006). It has been shown that 18F-FDG PET is 
more accurate than conventional modalities such as computed 
tomography, MRI, ultrasound, and physical examination 
for determination of the presence and extent of metastatic 
diseases (Finkelstein et al 2004; Swetter et al 2002). Because 
18F-FDG PET is highly sensitive and speciﬁ  c for the detection 
of metastatic melanoma thereby guiding the therapeutic 
planning, it can be used for surveillance after treatment in 
patients with high-risk stage III and IV melanoma (Delbeke 
1999; Fuster et al 2004; Macapinlac 2004).
Aside from the tumor tissue, 18F-FDG can also have 
significant uptake in other sites such as inflammatory 
tissue and the brown fat which may lead to false positives. 
Moreover, since the increased accumulation of 18F-FDG in 
melanoma cells is due to a higher metabolic rate than the 
normal cells, 18F-FDG is not a melanoma-speciﬁ  c imaging 
agent per se. Many other molecular targets or strategies 
have also been investigated for molecular imaging of 
melanoma.
Imaging integrin αvβ3
Integrins, a family of cell adhesion molecules, are involved 
in a wide range of cell-extracellular matrix and cell-cell 
interactions (Brooks et al 1994; Hood and Cheresh 2002). 
Integrins expressed on endothelial cells modulate cell 
migration and survival during angiogenesis while integrins 
expressed on carcinoma cells potentiate metastasis by 
facilitating invasion and movement across blood vessels. 
Each integrin molecule is consisted of noncovalently 
associated α and β subunits and at least 24 different integrins 
have been identiﬁ  ed (Ruoslahti 1996; Xiong et al 2001). The 
αvβ3 integrin, which binds to Arginine-Glycine-Aspartic 
acid (RGD)-containing components of the interstitial 
matrix (eg vitronectin, ﬁ  bronectin and thrombospondin), 
is significantly upregulated on endothelium during 
angiogenesis but not in quiescent endothelium (Brooks et al 
1994; Hood and Cheresh 2002). It is expressed in a wide 
variety of cancer types including melanoma. By activating 
and controlling many signaling pathways, integrin αvβ3 can 
enable melanoma cells to transform from stationary to a 
migratory and invasive phenotype (Kuphal et al 2005; Seftor 
1998). Several molecular imaging agents targeting integrin 
αvβ3 have been tested in animal models of skin cancer, one 
of which has already entered clinical development.
A 125I-labeled monomeric RGD peptide, c(RGDyV), was 
found to undergo predominately hepatobiliary excretion in 
an integrin αvβ3-positive M21 melanoma xenograft model 
(Haubner et al 1999). Therefore, glycosylated RGD-containing 
peptides were prepared to reduce the live uptake. Subsequently, 
a glycopeptide based on another peptide sequence, c(RGDfK), 
was labeled with 18F via a 2-18F-ﬂ  uoropropionate (18F-FPA) 
prosthetic group and the resulting 18F-galacto-RGD (Figure 3) 
exhibited receptor speciﬁ  c tumor uptake in the M21 melanoma 
model (Haubner et al 2001). This tracer was found to be quite 
stable in vivo. The intact fraction of 18F-galacto-RGD in the 
mouse blood, liver, kidney, and tumor was approximately 
87%, 76%, 69%, and 87%, respectively at 2 h post-injection. 
(Haubner et al 2004b).
Figure 2   The chemical structure of 18F-FDG and a PET scan showing extensive metastatic 
lesions (dark spots) of a melanoma patient.   Adapted from (Belhocine et al 2006).Clinical, Cosmetic and Investigational Dermatology 2008:1 8
Hong et al
18F-galacto-RGD has since been evaluated in the clinic 
and several studies have been reported, many of which 
involves melanoma patients. Initial study with nine patients 
of various tumor types revealed rapid, predominantly renal 
excretion of the tracer, resulting in fast tracer elimination from 
the blood and low tracer concentration in most of the organs 
(Haubner et al 2005). In tumor lesions, tracer accumulation 
showed great heterogeneity, with the standardized uptake 
values (SUVs) ranging from 1.2 to 10.0 (Figure 3). 
Subsequently, the biodistribution, pharmacokinetics, and 
human dosimetry of 18F-galacto-RGD was evaluated in groups 
of cancer patients including melanoma (Beer et al 2005; 
Beer et al 2006b). Reversed-phase high-performance liquid 
chromatography (RP-HPLC) of human serum revealed that 
more than 95% of tracer was intact up to 2 h post-injection 
and the highest absorbed radiation dose was in the bladder 
wall (8.14 ± 1.11 mGy/mCi), due to primarily renal excre-
tion of the tracer. In another study, patients with solid 
tumors were examined with 18F-galacto-RGD PET before 
surgical removal of the tumor lesions (Beer et al 2006a). 
Snap-frozen specimens were collected from representative 
areas with low and intense SUV of 18F-galacto-RGD for 
immunohistochemistry. The SUV value of the tumor ranges 
from 0.4 to 10.0 and there was a signiﬁ  cant correlation 
of SUV or the tumor/blood ratio with the intensity of 
immunohistochemical staining as well as with the microvessel 
density. These results suggested that 18F-galacto-RGD PET 
might be used as a new marker of angiogenesis and for 
individualized planning of therapeutic intervention.
Besides PET, various other modalities have been 
used for integrin αvβ3 imaging in small animal skin 
cancer models. An 111In-labeled nonpeptidic integrin αvβ3 
antagonist and a 99mTc-labeled RGD analogue has been 
evaluated for the visualization of αvβ3 integrin expression 
in nude mice bearing M21 melanoma tumors (Haubner et al 
2004a; Jang et al 2007). However, the pharmacokinetics 
and metabolic stability of the tracers was unsatisfactory for 
potential clinical application. Fluorescent dye conjugated 
RGD peptide has also been tested in M21 tumor models 
(Wang et al 2004). Only minimal difference of ﬂ  uorescence 
intensity was observed between the M21 and M21-L 
(integrin αvβ3-negative) melanoma tumors. Peptidomimetic 
integrin αvβ3 antagonist conjugated magnetic nanoparticles 
were tested in athymic nude mice bearing human melanoma 
tumors (Schmieder et al 2005). Very small regions 
(about 30 mm3) of angiogenesis associated with nascent 
melanoma tumors were visualized by this technique, which 
may potentially enable phenotyping and staging of early 
melanoma in a clinical setting.
Recently, cyanoacrylate microbubbles linked to multiple 
targeting ligands were employed to investigate the changes in 
molecular cancer marker expression during MMP inhibitor 
treatment in a HaCaT-ras-A-5RT3 SCC xenograft model 
(Palmowski et al 2008). One type of the ligand can bind to 
vascular endothelial growth factor receptor 2 (VEGFR-2) 
and the other type binds to αvβ3 integrin. Multi-marker 
imaging, achieved during the same imaging session, 
indicated a significant increase of VEGFR-2 and αvβ3 
integrin expression during tumor angiogenesis, as well as a 
considerable decrease in the density of both markers after 
treatment. This study suggested that targeted ultrasound may 
be feasible for longitudinal molecular proﬁ  ling of tumor 
angiogenesis and sensitive assessment of anti-angiogenic 
cancer therapy in vivo.
a bc
Figure 3 18F-galacto-RGD has been evaluated both preclinically and in melanoma patients. a) The chemical structure of 18F-galacto-RGD. b) The transaxial PET image of a nude 
mouse bearing a M21 human melanoma tumor (arrow) at 90 min post-injection. c) A patient with stage IIIb malignant melanoma and a solitary lymph node metastasis in the 
right axilla (arrow) was visualized by 18F-galacto-RGD. Adapted from (Haubner et al 2005).Clinical, Cosmetic and Investigational Dermatology 2008:1 9
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Dualmodality agents for both SPECT and optical imaging 
of αvβ3 integrin expression have been reported. c(RGDfK) 
was labeled with 111In and IRDye800 (emission maximum: 
800 nm) for gamma scintigraphy and continuous-wave 
imaging of M21 melanoma xenografts, respectively (Houston 
et al 2005). Twenty-four hours after administration of the 
agent at a dose equivalent to 90 µCi of 111In and 5 nmol 
of the NIR dye, whole-body gamma scintigraphy and 
optical imaging was conducted. It was found that while 
the target-to-background ratios of gamma scintigraphy 
and optical imaging were similar for superﬁ  cial tumors, 
the signal-to-noise ratio (SNR) was signiﬁ  cantly higher 
for optical than radionuclide imaging. Analysis of SNR 
versus contrast also showed that optical imaging has greater 
sensitivity for the subcutaneous tumor targets. However, such 
advantage quickly diminishes when the tissue of interest gets 
deeper under the skin ( a few mm). This proof-of-principle 
study demonstrated for the ﬁ  rst time the direct comparison 
of optical and planar radionuclide imaging for superﬁ  cial 
and sub-surface tumors. In another report, dualmodality 
ﬂ  uorescence and photoacoustic tomography imaging, using 
an integrin αvβ3-targeted peptide-dye conjugate in the M21 
xenograft model, enabled simultaneous visualization of the 
tumor location, angiogenesis, and the brain structure (Wang 
et al 2005).
Imaging integrin αvβ3 expression is one of the most 
vibrant ﬁ  elds of molecular imaging over the last 5 years (Cai 
and Chen 2008; Cai et al 2005; Cai et al 2008; Cai et al 2006). 
Since integrin is expressed not only in melanoma but also in 
many other tumor types (eg prostate, breast, brain and lung 
cancer), these integrin αvβ3-targeted agents can have broad 
application in cancer patient management in general. To date, 
very few of these agents have entered clinical development 
(Bach-Gansmo et al 2006; Haubner et al 2005; Kenny 
et al 2008; Sivolapenko et al 1998). Much future research 
effort (eg, moving more promising PET tracers into clinical 
evaluation in a timely manner) will be needed to achieve 
better sensitivity/speciﬁ  city in lesion (mainly metastatic 
melanoma) detection based on integrin αvβ3 imaging of skin 
cancer patients.
Imaging melanocortin-1 receptor
Melanocortin-1 receptor (MC1R), overexpressed in 
melanomas, is a promising melanoma-speciﬁ  c target for 
molecular imaging applications (Healy 2004; Sturm et al 
2003). To date, five melanocortin receptors (MC1R to 
MC5R) have been identiﬁ  ed and cloned (Mountjoy et al 
1992). More than 80% of human metastatic melanoma tumor 
samples have been found to express MC1R (Tatro et al 
1992). Radiolabeled alpha-melanocyte stimulating hormone 
(α-MSH) peptide analogues exhibit nanomolar MC1R 
binding afﬁ  nities, making them promising melanoma-speciﬁ  c 
imaging probes for lesion detection.
Two types of radiolabeled α-MSH peptides, linear 
and metal-cyclized, have been extensively studied (Miao 
and Quinn 2007). Currently, the most widely used linear 
α-MSH peptide analogue is 125I-[Nle4, D-Phe7]-α-MSH, often 
referred to as a “gold” standard due to its sub-nanomolar 
receptor binding afﬁ  nity (Chen et al 2000). Over the last 
decade, various α-MSH peptides have been radiolabeled 
with a dazzling number of different radionuclides including 
18F (Figure 4) (Cheng et al 2007b; Vaidyanathan and 
Zalutsky 1997), 99mTc (Chen et al 2002; Chen et al 1999; 
Giblin et al 1998; Miao et al 2007a), 111In (Bagutti et al 
1994; Chen et al 2002; Chen et al 2001; Cheng et al 2002; 
Froidevaux et al 2005; Froidevaux et al 2002; Miao et al 
2007a; Miao et al 2008b; Newton et al 2007), 125I (Chen 
et al 1999; Cheng et al 2004), 67Ga (Froidevaux et al 2004; 
Wei et al 2007b), 68Ga (Froidevaux et al 2004; Wei et al 





Figure 4 PET imaging of MC1R expression using an 18F-labeled α-MSH analog. a) The 
chemical structure of the PET tracer. b) Decay-corrected coronal PET images of mice 
bearing B16F10 (high MC1R expression) or A375M (low MC1R expression) melanoma 
tumor (arrows) at 1 h post-injection. Adapted from (Cheng et al 2007b).Clinical, Cosmetic and Investigational Dermatology 2008:1 10
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McQuade et al 2005; Wei et al 2007a), 186Re (Giblin et al 
1997),  203Pb(Miao et al 2008a), 188Re (Giblin et al 1998; 
Miao et al 2005c; Miao et al 2003), 90Y (Miao et al 2006; 
Miao et al 2005a), 177Lu (Miao et al 2006; Miao et al 
2005a; Miao et al 2007b), and 212Pb (Miao et al 2005b). 
Many of these radioisotopes are suitable for imaging only, 
while several others can also be used for internal radiotherapy 
applications.
Translating novel cancer imaging or therapeutic 
agents (eg, α-MSH based radiopharmaceuticals) from 
bench to bedside is time-consuming and quite expensive. 
Multiple steps in pre-clinical development, especially the 
investigational new drug-directed toxicology, signiﬁ  cantly 
slowed down this process. Therefore, although many of these 
abovementioned reports concluded/suggested that the agents 
developed had potential for metastatic melanoma imaging or 
peptide receptor-targeted radionuclide therapy, none of them 
have been tested yet in the clinical setting. With so many 
different agents developed for the same molecular target, 
it is rather difﬁ  cult to choose the right agent for clinical 
evaluation. On the other hand, it is certainly impractical to 
evaluate several agents of similar characteristics in the clinic 
due to the prohibitive cost. Whether the favorable results 
(both imaging and therapy) observed in small animal studies 
will hold true in melanoma patients remains to be validated 
in the future.
Imaging high molecular weight 
melanoma-associated antigen
Tumor-associated proteoglycans of human malignant 
melanoma were among the earliest to be explored for imaging 
applications. These HMWAs range from 100 kDa to 400 kDa 
in molecular weight. More than two decades ago, 131I-labeled 
Fab fragment of an anti-HMWA antibody was tested for 
preliminary feasibility studies of radioimmunodetection and 
radioimmunotherapy of patients with inoperable metastatic 
melanoma (Larson et al 1985). In ten patients, 17 of 23 (74%) 
documented metastases were detected by imaging with no 
false positives. Two patients who had avid tumor uptake 
subsequently received radiotherapeutic doses. Greater than 
50% reduction in the size of pelvic and pericaval nodes was 
observed, which remained stable for three months. Although 
subsequent studies revealed that melanoma metastases can 
also be identiﬁ  ed with either intravenous or subcutaneous 
injection of radiolabeled antibodies (Lotze et al 1986), the 
use of a Fab fragment is more advantageous than the intact 
antibody (IgG) because of the signiﬁ  cantly lower uptake 
in liver.
131I-labeled intact antibody (225.28S) and its F(ab’)2 
fragment, which recognizes HMWA, was evaluated in eight 
melanoma patients (Buraggi et al 1985). It was also found that 
the F(ab’)2 fragment is superior to the intact antibody in immu-
noscintigraphy, since it markedly reduced the background in 
the bone marrow, liver, and spleen. A report of  99mTc-labeled 
Fab fragment of an anti-HMWA antibody in twenty patients 
revealed that radioimaging with this radiopharmaceutical is a 
sensitive test, especially for detecting liver lesions (Lamki et al 
1990). Once again, it was conﬁ  rmed that biodistribution and 
imaging sensitivity of this Fab-based tracer differ signiﬁ  cantly 
from that of an 111In-labeled anti-melanoma IgG.
Several other radiolabeled monoclonal antibody (mAb) 
or antibody fragments recognizing HMWAs have also been 
reported in preclinical studies (Hamilton et al 2001; Le Doussal 
et al 1990; Svec et al 1989) and clinical studies (Sergieva and 
Virtcheva-Genkova 1997; Wahl et al 1990b). To reduce the 
nonspeciﬁ  c uptake of radiolabeled monoclonal antibodies 
in normal tissues, a signiﬁ  cant problem for tumor imaging, 
pre-dosing with cold, nonspeciﬁ  c, isotype-matched antibody 
before the injection of radiolabeled antibody was tested 
(Wahl et al 1987). Disappointingly, no decrease in tumor or 
normal tissue uptake was observed for either tumor-speciﬁ  c 
or nonspeciﬁ  c monoclonal antibodies after such pre-dosing. 
Therefore, high doses of isotype-matched unlabeled 
nonspeciﬁ  c mAb given before radiolabeled tumor-speciﬁ  c 
mAb will not enhance tumor imaging. The use of antibody 
fragments, rather than the intact antibodies, is still the preferred 
approach for achieving better tumor contrast.
A series of studies have been reported using ZME-018, 
a mouse anti-melanoma mAb. More than two decades 
ago,  111In-labeled ZME-018 was examined in thirty 
patients with metastatic malignant melanoma (Murray et al 
1987). Because intact mAb was used, nonspeciﬁ  c uptake 
of radioactivity was consistently observed in the liver and 
spleen. It was concluded that radioimmunolocalization 
of melanoma with 111In-ZME-018 was feasible and 
the sensitivity of the technique varies with the mAb 
dose, speciﬁ  c activity of the tracer, tumor size, and the disease 
site. Another study was then carried out to evaluate the 
radiation dosimetry and efﬁ  cacy of the 111In-labeled ZME-018 
in localizing metastatic lesions (Taylor et al 1988). Imaging 
was able to detect the lesion in 14 of 18 (78%) patients 
with active disease, and identify 24 of 44 (77%) lesions 
greater than 1cm. More importantly, imaging changed or 
speciﬁ  cally directed patient management in 22% (4/18) 
of the melanoma patients. Assuming a biodistribution 
similar to 111In-ZME-018, the radiation dose delivered to Clinical, Cosmetic and Investigational Dermatology 2008:1 11
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normal tissues by 90Y-ZME-018 would restrict its use for 
radioimmunotherapy although it can potentially deliver 
substantial tumor doses in selected patients.
ZME-018 has also been tested for delivering gelonin 
(a plant toxin), which was chemically conjugated to the 
antibody using different heterobifunctional crosslinking 
reagents, to antigen-positive human melanoma cells 
(Rosenblum et al 1999). Tissue distribution studies in 
tumor-bearing nude mice demonstrated that tumor uptake of 
the immunotoxin was similar to that of the intact antibody. 
Interestingly, the conjugate containing a recombinant gelonin 
was found to be more efﬁ  cacious than those conjugates 
incorporating natural gelonin.
A variety of anti-HMWA antibody and antibody fragments 
have been evaluated for melanoma imaging (Figure 5), most 
of which focused on the metastatic lesions. One common 
ﬁ  nding from these studies is that the use of an intact mAb is 
not optimal for either tumor imaging or tumor therapy. One 
way of improving the pharmacokinetics and tissue distribution 
proﬁ  le, as demonstrated from these reports, is to use smaller 
antibody fragments. We speculate that another form of 
antibody fragments not studied in the abovementioned reports, 
a diabody which has a molecular weight of about 55 kDa 
(Cai et al 2007b), may be a better alternative. Not only does 
a diabody clears from the circulation much faster than either 
mAb or F(ab’)2, which confers improved tumor contrast at 
early time points, it also preserves the bivalent antigen binding 
property which is more advantageous than either Fab or scFv 
fragments. Another approach to improve the tumor contrast 
is through pre-targeting, which typically requires the use of 
either biotinylated antibodies or bispeciﬁ  c antibodies (Gasparri 
et al 1999; Sharkey et al 2005).
Other molecular targets and strategies
A number of other agents have been investigated in animal 
models and melanoma patients. More than two decades ago, 
99mTc-labeled Nocardia soluble peptidoglycan derivative 
(which can bind to a model of activated macrophages) was 
evaluated for scintigraphic detection of melanoma metastasis 
(Le Pape et al 1986). The agent was encapsulated into 
liposomes and administered via the respiratory tract as an 
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Figure 5 Schematic structures of intact antibody and various antibody fragments.Clinical, Cosmetic and Investigational Dermatology 2008:1 12
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patients with a high risk of recurrent melanoma. Scintigraphy 
a few hours later revealed very small metastases, not seen 
by conventional scintigraphy, which was confirmed by 
histology. A 125I- and 111In-labeled mAb, speciﬁ  c for the 
G(D3) antigen, was tested in melanoma xenograft models 
(Lee et al 2001). In vivo localization of a radiolabeled 
anti-G(D3) mAb to G(D3)-expressing xenografts was 
observed with gamma camera imaging.
Lymphoseek, a 99mTc-labeled mannosyl-dextran that 
binds to mannose-binding protein (Vera et al 2001), is a agent 
designed for sentinel lymph node mapping. A phase I clinical 
trial was conducted to compare Lymphoseek with ﬁ  ltered 
99mTc-sulfur colloid (a particulate complex which can be 
taken up by the reticuloendothelial system) for melanoma 
sentinel lymph node detection in patients (Wallace 
et al 2007). No adverse events were observed. Further, 
Lymphoseek exhibited faster injection site clearance and 
equivalent primary sentinel node uptake than the ﬁ  ltered 
99mTc-sulfur colloid.
Besides gamma camera and/or SPECT imaging, several 
other modalities have also been reported for imaging 
melanoma. MRI of human epidermal growth factor receptor 
2 (HER2 (Cai et al 2007a)) and 9.2.27 tumor antigens were 
performed in a panel of cultured melanoma and mammary 
cell lines, using antibody conjugated monocrystalline iron 
oxide nanoparticles (Funovics et al 2004). It was found that 
anti −9.2.27 conjugates bound to the plasma membrane while 
the anti-HER2 conjugates underwent receptor-mediated 
endocytosis.
A ﬂ  uorescent deoxyglucose analog was reported for 
tumor imaging in an A375M melanoma model (Cheng 
et al 2006). However, both the glucose analog and a non-
speciﬁ  c control exhibited tumor (cell) uptake in cell culture 
and living mice. Such low speciﬁ  city is likely due to the 
much larger size of the dye than the glucose analog, which 
significantly affects its cellular uptake by the glucose 
transporters and hexokinase. A 64Cu-labeled antibody 
against disialogangliosides, overexpressed in melanoma, 
was tested in nude mice bearing subcutaneous melanoma 
tumors (Voss et al 2007). The conjugate was shown to have 
high speciﬁ  c activity, antigen binding afﬁ  nity, and in vivo 
target speciﬁ  city.
A recent proof-of-concept study utilized electron 
paramagnetic resonance (EPR) imaging, which detects 
the naturally occurring free radicals in melanin pigments, 
for melanoma imaging (Vanea et al 2008). The potential 
of EPR in imaging melanoma samples was demonstrated 
in vitro using both animal and human samples. Upon 
further development and optimization, this technology may 
potentially advance the diagnosis of suspected melanoma 
lesions.
Summary and outlook
Big strides have been made in anatomical and molecular 
imaging of skin cancer. Although both types of imaging 
techniques can play a role in any skin cancer subtypes, it 
appears that anatomical imaging will be more useful/relevant 
in nonmelanoma while molecular imaging plays a more 
important role in melanoma and melanoma metastasis. Most 
of the anatomical imaging techniques do not require contrast 
agent, therefore much clinical data are available. On the 
other hand, almost all molecular imaging techniques require 
a molecular probe to be administered, which typically takes 
a long time from initial development to ﬁ  nal approval for 
clinical use. Thus it is not surprising that most of the clinical 
data for molecular imaging of skin cancer is about PET 
imaging after injection of 18F-FDG (the only PET agent that 
has gained approval for cancer imaging from the Food and 
Drug Administration).
Interestingly, a signiﬁ  cant portion of the clinical data 
regarding molecular imaging of skin cancer (mostly 
melanoma) comes from about 20 years ago, although at 
that time the term “molecular imaging” has not been widely 
spread across the scientiﬁ  c community. The explosion of 
molecular imaging research over the last decade is partially, 
if not mostly, due to the increasingly wider availability of 
scanners dedicated to small animal studies. However, with 
an overwhelming number of animal studies reported every 
week, clinical translation has become more and more difﬁ  cult 
in the United States due to many regulatory constraints. For 
example, α-MSH peptide analogs have been labeled with 
a wide variety of radioisotopes over the last decade, yet no 
clinical data has been report so far. With the ultimate goal 
being early diagnosis and monitoring therapy in cancer 
patients, the current status of clinical molecular imaging is 
by no means satisfactory or healthy.
Many scientiﬁ  c societies have recently tried to work 
with the regulatory agencies (most notably the Food and 
Drug Administration) in order to reduce the prohibitively 
expensive requirements before initial clinical evaluation 
of molecular imaging agents, especially PET/SPECT 
agents since they are administered at doses many orders 
of magnitude below the pharmacologically active level. 
The situation will have to change over the next several 
years, otherwise the whole ﬁ  eld of molecular imaging will 
collapse. Preclinical molecular imaging is thriving all over Clinical, Cosmetic and Investigational Dermatology 2008:1 13
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the world, while clinical molecular imaging has not lived up 
to the expectations. It is quite discouraging that 18F-FDG is 
still the only PET tracer approved for clinical use, at more 
than thirty years after the invention of the PET scanner. Many 
more molecular imaging agents should be evaluated in cancer 
patients, as 18F-FDG is certainly not sufﬁ  cient for melanoma 
detection, staging, and treatment monitoring.
It has been generally accepted that the occurrence of 
many cancer types depends on the life style. For example, 
about 90 percent of NMSCs are associated with exposure to 
ultraviolet radiation from the sun (Armstrong and Kricker 
1993). Sunlight is the also the main environmental agent 
that causes melanoma, although the exact wavelengths of 
sunlight are currently unknown. Perhaps such is the price 
we have to pay for enjoying the sunshine on the beach? 
Studies have shown that early detection is the key to cure 
cancer. When the tumor is still localized to its tissue of 
origin, a skilled surgeon can cure a cancer patient in most 
cases. Metastasis is the primary killer of cancer patients, 
which is especially true for skin cancer where the mortal-
ity is mostly due to melanoma metastasis. With many 
molecular imaging agents currently in preclinical and 
clinical development (Figure 6), it is very likely that some 
of the molecularly speciﬁ  c agents will ﬁ  nally succeed in 
the clinic to allow for accurate early detection/diagnosis of 
skin cancer. The future is bright, yet many hurdles remain 
to be overcome and much further research/validation needs 
to be carried out.
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